Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials

Journal of Invasive Cardiology

Volumn 20, Issue 8, 2008, Pages 417-422

  Sanchez Recalde, Angel ^a   Moreno, Raul ^a   Barreales, Laura ^b   Rivero, Fernando ^c   Galeote, Guillermo ^a   Jimenez Valero, Santiago ^a   Calvo, Luis ^a   López De Sá, Esteban ^a   López Sendón, José L ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Complications; Interventional cardiology; Intravascular ultrasound; Stents

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ARTICLE; BARE METAL STENT; CHI SQUARE TEST; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FOLLOW UP; HUMAN; IMPLANTATION; INTRAVASCULAR ULTRASOUND; LATE ACQUIRED INCOMPLETE STENT APPOSITION; META ANALYSIS; PROSTHESIS LOOSENING; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; DRUG-ELUTING STENTS; HUMANS; METALS; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 48749083011     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Moreno R, Fernandez C, Sanchez-Recalde A, et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 2007;28:1583-1591.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: Comparison with bare metal stents by serial intravascular ultrasound analyses: Data from the randomized TAXUS-II trial. Circulation 2004;109:196-200.
4. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
6. Mauri L, Hsieh W-h, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
7. Waksman R. Late thrombosis after radiation. Sitting on a time bomb. Circulation 1999;100:780-782.
8. Holmes DR, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents. An objective appraisal. J Am Coll Cardiol 2007;50:109-118.
9. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents. Evolving concepts and perspectives. J Am Coll Cardiol 2007;50:119-127.
10. Hong MK, Mintz GS, Lee CW, et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004;109:881-886.
11. Siqueira DA, Abizaid AA, Costa Jde R, et al. Late incomplete apposition after drug-eluting stent implantation: Incidence and potential for adverse clinical outcomes. Eur Heart J 2007;28:1304-1309.
12. Tanabe K, Serruys PW, Degertekin M, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: Insights from the randomized TAXUS II trial. Circulation 2005;111:900-905.
13. Weissman NJ, Koglin J, Cox DA, et al. Polymer-based paclitaxel-eluting stents reduce instent neointimal tissue proliferation: A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1201-1205.
14. Weissman NJ, Ellis SG, Grube E, et al. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: A volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J 2007;28:1574-1582.
15. Mintz GS, Weissman NJ, Dawkins K, et al. Frequency, predictors, and clinical outcomes of late-acquired incomplete stent apposition in patients treated with Taxus stents: a volumetric intravascular ultrasound meta-analysis from Taxus IV, V, and VI trials. J Am Coll Cardiol 2006; 47 Suppl B:26B.
16. Weissman NJ. Taxus V IVUS. Deep insights into long lesions. Paris Course on Revascularization Annual Meeting, 2005. Available at: http://www. europcronline.com/fo/lecture/ affiche_diapo.php?id=1755. Accessed July 9, 2007.
17. Weissman NJ. IVUS insights from the Taxus clinical trials. Transcatheter Cardiovascular Therapeutics Annual Meeting, 2004. Available at: http://www.tctmd.com/csportal/appmanager/ tctmd/main?nfpb=true&pageLabel= TCTMDContent&hdCon=757557. Accessed July 8, 2007.
18. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: A serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003;107:517-520.
19. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: Angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-1954.
20. Knopf WD. DELIVER I. Final results and afterthoughts. Transcatheter Cardiovascular Therapeutics Annual Meeting, 2003. Available at: http://www.tctmd.com/csportal/ appmanager/ tctmd/main?_nfpb=true&_pageLabel= TCTMDContent&hdCon=868543. Accessed July 8, 2007.
21. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
22. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: A serial intravascular ultrasound analysis. J Am Coll Cardiol 2005;46:1002-1005.
23. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: Three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-2179.
24. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
25. Wijns W, Fajadet J, Kuntz RE. A randomized trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578 eluting driver coronary stent in de novo native coronary artery lesion. TCT Annual Meeting, 2004. Available at: http://www.tctmd.com/csportal/appmanager/ tctmd/descoe?_nfpb-truece_page_label- DESCenterContent/&hdCon-1054156. Accessed July 10, 2007.
26. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006;98:464-469.
27. Tsuchida K, Piek JJ, Neumann FJ, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointerv 2005;1:266-272.
28. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-1900.
29. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalysis. BMJ 2003; 327:557-560.
30. Higgins JPT, Thompson SG. Quanifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
31. Shah VM, Mintz GS, Apple S, Weissman NJ. Background incidence of late malapposition after bare-metal stent implantation. Circulation 2002:106:1753-1755.
32. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-419.
33. Miyazawa A, Tsujino I, Ako J, et al. Characterization of late incomplete stent apposition: A comparison among bare-metal stens, intracoronary radiation and sirolimus-eluting stents. J Invasive Cardiol 2007;19:515-518.
34. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation 2003;107:2660-2663.
35. Hoffmann R, Morice MC, Moses JW, et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: Intravascular ultrasound analysis from the multicenter, randomized, RAVEL, E-SIRIUS and SIRIUS trials. Heart 2008; 94;322-328.
36. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-2434.
37. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
38. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
39. Mintz GS. What to do about late incomplete stent apposition? Circulation 2007;115:2379-2381.